Scientists grew 49 mini guts from 27 kids and injected their own gut bacteria

If your child has inflammatory bowel disease, you have probably been told that their immune system is reacting badly to their gut bacteria, and then handed a drug chosen largely by educated guesswork. Years of switching between biologics, immunosuppressants and diets is a normal paediatric IBD story, and nobody can tell you in advance which one your child's gut will respond to. A team at Monash University has now built something that gets closer to the actual problem: living miniature copies of a child's own intestinal lining, with bacteria taken from that same child's gut wall injected back inside them. The result, published in Scientific Reports, is not a treatment. It is a way of asking the question that treatment decisions currently skip.

Key takeaways

• Researchers built matched pairs for 27 paediatric patients: lab-grown gut lining from a biopsy, plus live bacteria cultured from a second biopsy taken at the same moment, from the same spot.
• Two bacteria that were near genetic twins, 96.96% identical, did opposite things. The strain from a healthy control switched on inflammatory signalling in the gut lining. The strain from an IBD patient did not, but it made the lining leakier.
• Bacteria only provoked a response when injected inside the organoid, touching the lining the way they would in a real gut. Floating in the surrounding fluid, they did nothing.
• This is a laboratory platform, tested on four bacterial isolates. No child's treatment has been chosen this way, and the authors describe their own conclusions as speculative given the small numbers.

Matched gut organoids and mucosa-attached bacteria from 27 children

Eva Chan, Edward Giles, Samuel Forster, Helen Abud and colleagues at the Monash Biomedicine Discovery Institute created a biobank of 49 intestinal organoid lines grown from 27 paediatric patients, alongside 538 live bacterial isolates cultured from the same children's gut walls. An organoid, in plain terms, is a self-organising clump of real human cells grown from stem cells in a dish. These ones are hollow balls of intestinal lining, with the surface that normally faces the inside of the gut turned inward, so they behave like a tiny closed intestine a fraction of a millimetre across. They are not mini-organs with nerves and blood vessels. They are the lining, alive, and belonging to a specific named child.

The children were recruited while undergoing gastroscopy and colonoscopy, and the IBD patients were sampled at diagnosis, before treatment started, so no drug effects muddy the picture. Patients with known or suspected monogenic disorders were excluded. Tissue came from two sites in the small intestine, the duodenum (the first stretch after the stomach) and the terminal ileum (the last stretch before the colon). Bacteria could only be cultured from the terminal ileum; the duodenum carries too small a bacterial load. Of the 538 isolates, 320 were Bacteroidota, 105 Bacillota, 89 Pseudomonadota, 16 Actinomycetota and 8 Fusobacteria, with 27 of them apparently belonging to species not previously described.

Why paediatric IBD is the population this matters to

Children diagnosed with Crohn's disease or ulcerative colitis get a more aggressive version of the illness than adults do, with lifelong consequences for growth and nutrient absorption, which is exactly why researchers keep trying to catch it at diagnosis. IBD itself is understood as an abnormal immune reaction to gut bacteria in a genetically susceptible person, with more than 300 genetic risk regions identified so far. But the standard way of studying a patient's microbes is to sequence their stool, and stool bacteria are not the same population as the ones physically stuck to the gut wall, where the immune interaction actually happens. This study's central move is to skip stool entirely and grow the bacteria that were clinging to the mucosa, next to the cells they were irritating.

The dual biopsy protocol that makes the model patient-specific

The methodological trick is unglamorous and important: two biopsies, taken at the same site during the same procedure, one processed for bacteria and one for tissue. Bacteria were released by vortex mixing and plated anaerobically, while the epithelial cells were mechanically dissociated and embedded in Matrigel to grow into organoids. That means every bacterial isolate has a matched host, and every organoid has a matched set of its own microbes. Organoids grew equally well from control and IBD tissue.

RNA sequencing on 36 organoid lines from 18 patients (7 control, 7 Crohn's, 4 ulcerative colitis) produced a result worth sitting with: the organoids clustered by where in the gut they came from, not by whether the child had IBD. Within each site there were real differences by diagnosis. Duodenal organoids showed 19 genes differentially expressed between Crohn's and control, 156 between ulcerative colitis and control. Terminal ileum organoids showed 9 and 284 respectively. Ulcerative colitis organoids from both sites turned up MHC class II antigen-presentation genes such as HLA-DRA and HLA-DRB1, a sign of immune signalling in tissue that is not where ulcerative colitis is supposed to live. The authors are careful to say the small numbers make this speculative.

Two near-identical bacteria, two opposite effects on the gut lining

The most striking result came from microinjection: using a fine needle to place live bacteria into the hollow centre of an organoid, so they contact the inward-facing surface of the lining exactly as they would in a real gut. The team picked four isolates forming two closely related pairs, one member of each pair from a control child and one from an IBD child.

The Enterobacteriaceae pair, 96.96% identical at the genome level, behaved completely differently. Isolate CC00517, from a control patient, switched on inflammatory signalling in both control-derived and IBD-derived organoids: chemokine genes CXCL1, CXCL2, CXCL3 and NFKBIA, with gene-set analysis pointing to TNF-alpha and IL-17 signalling, the very pathways that IBD biologics target. Its IBD-derived near-twin CC00518 did not. Instead, CC00518 increased the leakiness of the lining, measured as loss of an injected fluorescent tracer over 24 hours (p = 0.0015). Crucially, CC00517's inflammatory effect appeared only when it was injected inside the organoid, not when it was simply added to the surrounding fluid. Side of the cell matters. The other pair, from the Bacteroidaceae family, produced almost no transcriptional response at all.

What this does and does not mean if you are managing IBD

Nothing here changes what you should do this week. There is no test to ask for, no bacterium to avoid, no supplement implied. What is genuinely worth understanding is the conceptual shift: an inflammatory signal in the gut lining came from a bacterium isolated from a healthy child, which undercuts the tidy idea that IBD is caused by identifiable bad bugs. The authors' reading is that inflammation is a normal part of how the epithelium senses commensal bacteria, and that IBD may be a failure to modulate that response rather than the presence of a villain. If a clinician ever offers your family a microbiome-based intervention framed as removing bad bacteria, that framing is doing more work than the evidence supports. The reasonable thing to ask a paediatric gastroenterologist is whether your child's centre participates in tissue biobanking at diagnosis, since these platforms only exist where samples were collected.

The limits: four isolates, no immune cells, one lab

The authors are unusually direct about what their model cannot do. The organoids contain epithelial cells only, with no immune cells or mesenchymal cells, so the full inflammatory cascade of real IBD is absent by construction. Microinjection is, in their words, labour-intensive, which caps the experiment at four isolates when a real microbiome contains hundreds. Because injection happens in air, only oxygen-tolerant bacteria could be tested, excluding most gut anaerobes. Organoid passage number may confound the transcriptional data. The whole thing comes from one group and has not been independently replicated, and there are no patient outcomes of any kind, because no patient was treated. The authors declare no competing interests, and the organoids, bacterial isolates and sequencing data have been deposited publicly.

What comes next: scaling past the needle

The stated next step is throughput, not the clinic. The team explicitly proposes moving to more scalable formats, such as growing organoids as flat two-dimensional layers on filters, so that many bacterial isolates can be screened at once rather than one needle at a time. Adding immune and mesenchymal cells to the cultures is the other named direction. Only after that does the ambition the press coverage led with, testing a child's own gut against their own bacteria before choosing a therapy, become testable, and it would then still need prospective clinical trials. No timeline is given, and none should be inferred.

Common questions

What is an intestinal organoid, in one sentence? It is a millimetre-scale ball of living human gut lining grown from stem cells taken in a biopsy, which forms a hollow interior mimicking the inside of the intestine. It is real human tissue from a specific person, but it lacks immune cells, nerves and blood supply.

Does this mean bacteria from healthy people can cause inflammation? In this dish, yes: an isolate from a control child triggered TNF and IL-17 signalling in the epithelium. The authors interpret this as normal immune surveillance of commensal bacteria rather than harm, since an inflammatory response is part of how the gut lining monitors its residents.

Could my child's IBD treatment be chosen this way now? No. This is a proof-of-concept research platform involving 27 tissue donors and four bacterial isolates, with no patient treatment outcomes and no independent replication. Personalised therapy selection is the goal the researchers are working toward, not something the study demonstrates.

Why the duodenum and terminal ileum rather than the colon? The terminal ileum was chosen because it is common to all IBD subtypes and is a site of intense immune interaction with the microbiome, and both small-intestinal sites are understudied compared with the colon. That also means the colon, where ulcerative colitis actually presents, was not sampled for organoids here.

References

1. (2026). Lab-grown 'mini guts' to help kids with inflammatory bowel disease – Monash University. https://www.monash.edu/discovery-institute/news-and-events/news/2026-articles/lab-grown-mini-guts-to-help-kids-with-inflammatory-bowel-disease
2. Iliyan D. Iliev, Ashwin N. Ananthakrishnan, Chun-Jun Guo (2025). Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nature Reviews Microbiology. https://doi.org/10.1038/s41579-025-01163-0
3. GEO accession GSE288179 — transcriptional data from the study. NIH. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288179